Innovation is at the heart of our activities. Having pioneered the sublingual immunotherapy segment, we now aim to search for new therapeutic solutions that address current unmet allergy patient needs
Our research and development is aimed at:
Understanding the allergy’s fundamental immune mechanisms and their modification through allergy immunotherapy, as well as the molecular structure of allergens.
Evolving diagnostic products and existing treatments at the same pace as technical and scientific advances and regulatory changes.
Specifying the indications of immunotherapy depending on allergens, patient symptoms and treatment delivery methods with more precision, using clinical trials.
Perfecting innovative products which are more effective and easier to use, relying on new biotechnological advances.
Each year, Stallergenes Greer invests around 20% of its annual turnover in Research & Development to be able to offer state-of-the-art medicines. More than 10,000 patients were enrolled in sublingual clinical studies.